Car dealership Pendragon felt the pinch of the new car pricing issue and also revealed that it would use funds from property disposed of last year to buy back its own shares. The board still claimed the full year performance was 'creditable' due to consumer confidence being at an all-time low. Preliminary figures to 31 December showed a dip in sales from £1.8bn to £1.43bn, with pre-tax profits slumping to £4.1m (£19.2m). Operating and other exceptional costs of £5.4m were charged, whereas the 1999 figure of £19.2m was arrived at after crediting £5.7m. Losses also hit home within the contract hire business because of a fall in used car residual values over the past year. Furthermore, an extra £3.4m of interest arose because Pendragon borrowed to make several acquisitive moves. In March the firm bought 32 dealerships and 4 bodycentres from Lex for £82.5m which enhanced its luxury and specialist car offering. Two Jaguar dealerships were acquired in Germany and Pendragon made inroads into the US through the 'Bauer Motors' purchase. On a more positive note, the group launched an internet sales operation, tins.co.uk, and also revealed a tie-up with Microsoft. Trading in December and January has been ahead of expectations and the board believes there are signs of consumer confidence returning.
Market cap: £141.4m
PE Forecast: 7.8
Share price: 232p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.